Summary : Five Prime’s lead asset, Bemarituzumab, is a first-in-class, Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled…
ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved.
Designed and Developed by Ample eBusiness